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Abstract
Background: Sutures colonized by bacteria represent a challenge in surgery due to their potential to cause surgical
site infections. In order to reduce these type of infections antimicrobially coated surgical sutures are currently under
development. In this study, we investigated the antimicrobial drug octenidine as a coating agent for surgical
sutures. To achieve high antimicrobial efficacy and required biocompatibility for medical devices, we focused
on optimizing octenidine coatings based on fatty acids. For this purpose, antimicrobial sutures were prepared
with either octenidine-laurate or octenidine-palmitate at 11, 22, and 33 μg/cm drug concentration normalized
per length of sutures. Octenidine containing sutures were compared to the commercial triclosan-coated suture Vicryl®
Plus. The release of octenidine into aqueous solution was analyzed and long-term antimicrobial efficacy was assessed
via agar diffusion tests using Staphylococcus aureus. For determining biocompatibility, cytotoxicity assays (WST-1) were
performed using L-929 mouse fibroblasts.
Results: In a 7 days elution experiment, octenidine-palmitate coated sutures demonstrated much slower drug release
(11 μg/cm: 7 %; 22 μg/cm: 5 %; 33 μg/cm: 33 %) than octenidine-laurate sutures (11 μg/cm: 82 %; 22 μg/cm: 88 %; 33
μg/cm: 87 %). Furthermore sutures at 11 μg/cm drug content were associated with acceptable cytotoxicity according
to ISO 10993–5 standard and showed, similar to Vicryl® Plus, relevant efficacy to inhibit surrounding bacterial growth
for up to 9 days.
Conclusions: Octenidine coated sutures with a concentration of 11 μg/cm revealed high antimicrobial efficacy and
biocompatibility. Due to their delayed release, palmitate carriers should be preferred. Such coatings are candidates for
clinical testing in regard to their safety and efficacy.
Keywords: Surgical sutures, Antimicrobial, Coating, Octenidine, Slow-release, Fatty acid, Staphylococcus aureus,
Surgical site infection, Biocompatibility, In vitro
Background
Surgical site infection (SSI) is a common complication
after surgical intervention and incidence for SSI can be
as high as 25 %, depending on the anatomical location
of the surgical site [1–5]. The onset of SSI has been as-
sociated with a variety of factors, including surgical
sutures [6]. The property of surgical suture for adhering
bacteria promotes the occurrence of such infections [7].
The use of antimicrobially coated sutures poses one
possible approach to prevent or reduce suture-associated
infections. At present, the only commercially available
antimicrobial sutures are coated with triclosan, such
as the resorbable multifil Vicryl® Plus [8]. Several in
vitro studies reported that triclosan-incorporated su-
tures showed high antimicrobial activity against a
broad spectrum of pathogens [9–11]. Dependent on
the surgery site, the clinical benefit of such coated su-
tures varies. On the one hand, no benefit was reported
in studies for appendicitis, breast cancer or colorectal
surgery [3, 12–14]. In contrast, the use of antimicro-
bial coated sutures in sternum surgery [15], abdominal
wall closure [16, 17] and cerebrospinal fluid shunting
procedures [18] was associated with significantly lower
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wound infection rates. Moreover, a recent meta-
analysis showed a significant benefit of triclosan
coated sutures to prevent surgical site infection [19].
However, due to its wide use in health-care, household
and cosmetic items triclosan resistance is frequently re-
ported for S. aureus a common pathogen in wound infec-
tions [20]. Furthermore the promotion of multi drug
resistances in the presence of triclosan via increased activity
of efflux pump system is a major concern [21]. Screening
tests performed between 2003 and 2004 already demon-
strated detection of triclosan in the urine of 74.6 % of US
citizens [22, 23]. Therefore, the development of sutures
with different antimicrobial drugs is urgently required.
In a previous study, we established a coating process
to render surgical sutures antiseptic, while meeting the
European Pharmacopoeia requirements for the material
strength of surgical sutures [24, 25]. We showed that su-
tures coated with the antimicrobial drug chlorhexidine
pose a highly efficient alternative with low cytotoxicity to
the established antimicrobial sutures using triclosan, such
as Vicryl® Plus. Furthermore we demonstrated a strongly
dose dependent efficacy and biocompatibility. However,
the antimicrobial effect lasted up to 4 days and biocom-
patibility was also limited. Therefore, we chose the anti-
microbial drug octenidine for further development of
suture coatings. Octenidine is well established in skin and
wound antiseptic solutions, and even recommended as
potential alternative in case of triclosan resistance [26].
Further, this antiseptic drug has a broad-spectrum activity,
including common pathogens of wound infections such as
multiresistant bacteria [27]. In addition, the lower solubil-
ity in aqueous medium may result in slower drug release,
with longer efficacy against pathogens and lower cytotox-
icity compared to chlorhexidine coatings.
The aim of the present study was the development of
antimicrobial octenidine containing formulations based on
fatty acids. We focused on optimizing drug concentrations
in order to achieve improved long-term antimicrobial effi-
cacy and biocompatibility concerning resorbable su-
tures. Both antimicrobial efficacy over several days, as
well as cytotoxicity of novel coated octenidine contain-
ing sutures were compared to commercially available
plain polyglycolic acid (PGA) and triclosan containing
sutures like Vicryl® Plus.
Methods
Surgical sutures
Sutures in our study had diameters according to United
States Pharmacopeia (USP 1). The used suture consists
of polyglycolic acid (PGA, Gunze Ltd., Japan), free of
fatty acids to avoid sewing effect. Our investigations
were compared with reference sutures (PGA Resorba®,
Resorba Medical GmbH, Germany; Vicryl® and Vicryl®
Plus, Ethicon GmbH, Germany).
Antimicrobial coating solutions
Antimicrobial coating solutions were prepared as follows:
Either palmitic or lauric acid together with octenidine
were dissolved in 99.8 % ethanol (Carl Roth GmbH,
Germany). The solutions contained 395.0 mg of both
components fatty acid and octenidine in 7.9 g (10.0 ml)
ethanol, which corresponds to a mass content of 5 %
(w/w). Under aseptic conditions, the solutions had to
be homogenized and filtered (minisart, sartorius AG,
Germany, pore size 0.2 μm). Two types of coating were
produced: Octenidine dihydrochloride (Dishman Pharma-
ceuticals & Chemicals Ltd., India) in lauric acid (OL) and
Octenidine dihydrochloride in palmitic acid (OP). Both
for OL and OP, three different antiseptic drug concentra-
tions inside coating solutions were chosen: 20 %, 40 % and
60 % (w/w), respectively (Table 1 a).
Preparation of antimicrobial sutures
The sutures (40 cm in length, n = 7) were coated in a
dipping process with the prepared antimicrobial coating
solutions using a thermo-shaker (Heidolph Instruments
GmbH, Germany) for 2 min at 35 °C at 150 rpm. Subse-
quently, sutures were fixed on a device and dried for 2 h
(h) at room temperature. After this drying process, the
coating weight was determined by using a precision
Table 1 Octenidine fatty acid coating of sutures with 40 cm in length and the resulting concentrations
a) Coating solutions b) Resulting antimicrobial suture preparation
Coating type Ratio of octenidine











octenidine-laurate OL11 20 % 79.0 316.0 0.44 1.76 11
octenidine-palmitate OP11
octenidine-laurate OL22 40 % 158.0 237.0 0.88 1.32 22
octenidine-palmitate OP22
octenidine-laurate OL33 60 % 237.0 158.0 1.32 0.88 33
octenidine-palmitate OP33
a) Drug and fatty acid components were applied at given ratios above and dissolved in 10.0 ml ethanol to produce the specific coating solutions with 5 % mass
(w/w). b) Octenidine content of coated sutures after preparation. The mean coating weight of 40 cm suture samples were determined at 2.2 ± 0.2 mg (n = 7).
Weights on coated sutures for octenidine, fatty acid carrier and normalized mean drug weight per cm thread are given above
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balance (Atilon ATL-224; Acculab Inc., Massachusetts,
USA). The drug amount normalized per length of su-
tures (μg/cm) was calculated for each drug concentra-
tion (20 %, 40 %, 60 %) via the measured coating weight
(Table 1 b). Finally, coated sutures of 10 cm length were
vacuum-sealed in sterile polyethylene bags and stored
at room temperature. At the beginning of the experi-
ments, coated sutures were cut into 1 cm, 2 cm and
3 cm long samples.
Antimicrobial efficacy of coated sutures via agar diffusion
test
Antimicrobial efficacy of sutures was tested via the agar
diffusion test (n = 3) compared to Vicryl® Plus. According
to CLSI criteria, suspensions of Staphylococcus aureus
(ATCC® 49230™) were prepared to an optical density of 0.5
McFarland standard. Then, 1 ml of this suspension was
plated uniformly on Mueller Hinton II Agar plates with
90 mm standard size. After removal of the supernatant
and drying the petri dishes, suture samples were placed
on the inoculated Agar plates and incubated at 37 °C
overnight. After 24 h, zones of inhibitions were mea-
sured in millimeter (mm) by using a calliper perpen-
dicular to the sutures. According to Ming et al. [10],
this procedure was repeated daily by using the same su-
ture samples for several days to recognize the
remaining anti-bacterial activity until no detectable in-
hibition zone remained.
Octenidine release from laurate and palmitate coatings
The octenidine release kinetics of the coated sutures
were analysed over a period of 168 h in phosphate-
buffered saline (PBS) at pH = 7.4. Sutures of 2 cm length
(n = 6) were put in 1.5ml-cups (Eppendorf AG,
Germany) with 1 ml PBS at 37 °C in a thermomixer
MHR 23 (HLC-Biotech, Germany) at 200 rpm. Elution
media was replaced by fresh PBS at fixed time intervals
(after 0.5 h, 1.5 h, 3.5 h, 5.5 h, 7.5 h, 24 h, 48 h, 72 h, 96
h, 120 h, 144 h and 168 h). The release of octenidine
was measured by absorption at a wavelength of 280 nm
in a microplate photometer (Multiskan Go; Thermo
Fisher Scientific GmbH, Germany). The amount of mea-
sured octenidine was normalized to the length of suture
samples. Drug elution profiles were recorded by cumu-
lating the released drug amounts over time. Ratios of the
released octenidine were calculated relating to the drug
content on suture samples at 168 h, depending on octe-
nidine concentration of coated sutures.
Biocompatibility study
In accordance with both the ISO 10993–5 guideline and
the WST-1 assay instruction, analysis of in vitro cytotoxicity
of coated sutures was performed by using mouse fibroblasts
L-929 (ACC 2; DSMZ, Germany) and measuring the
metabolic activity of cells in the presence of eluates from
coated sutures. Cell cultures grew in the corresponding
Dulbecco's Modified Eagle Medium (DMEM with 4.5 g/l
D-glucose, Biochrom AG, Germany) consisting of 10 %
fetal bovine serum at 37 °C and 5.0 % CO2 in a humidified
atmosphere. Each well of a 96 well microtiter plate was
filled with 10.000 cells and 200 μl DMEM, followed by in-
cubation over 24 h. Eluates were generated simultaneously
by placing coated sutures (n = 7) of 1 cm in length in 2 ml
tubes containing 1.5 ml DMEM, for 24 h on a thermomixer
at 37 °C and 300 rpm. Subsequently, cell culture’s media
were replaced by the eluates after 24 h. After 48 h, each
well was supplemented with 20 μl WST-1 reagent to
commence cell reaction to generate formazan salts by
cellular mitochondrial dehydrogenases. After a reaction
time of 2 h at 37 °C, the amount of formazan salts was
detected at 450 nm in an absorption reader. Metabolic
activities were referred to L-929 cells used as growth
reference without sutures. A threshold of 70 % accord-
ing to ISO 10993–5 standard was used to claim “bio-
compatibility” for drug eluting sutures.
Statistics
Statistical analysis was conducted by using the student’s
t-test with significant level p < 0.05. Measurements based
on mean values and standard deviations from at least
three values. The Gaussian error propagation law was
used to correct mean value calculations from several
measurements.
Results
Reproducibility of antimicrobial suture coatings
Independently from the drug concentrations used, the
mean coating weight - the difference between the un-
coated and coated sutures of 40 cm in length was 2.2
mg ± 0.2 mg (n = 7). The amount of octenidine, fatty acid
and the normalized amount of drug per length of thread
was calculated for each drug concentration relative to
this mean coating weight; 11, 22 and 33 μg/cm, respect-
ively (Table 1). The weight of the triclosan containing
Vicryl® Plus sutures was 2.7 μg/cm [28, 29], as declared
by the manufacturer.
Antimicrobial efficacy of coated sutures via agar diffusion
test
Lauric and palmitic coating of octenidine kept zones of
inhibition relatively stable from the second to the ninth
day of experiments from 1.9 mm to 1.6 mm at day 9
(Fig. 1). On the tenth day, experiments were discontin-
ued because the threads lost stability by humidity on
agar plates and could not be transferred anymore. Long-
term protection was detected for the three drug concen-
trations, without depletion of the antimicrobial efficacy.
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Triclosan coated sutures (Vicryl® Plus) demonstrated
zones from 19.8 mm to 1.7 mm of microbial inhibition
for the same observation period (Fig. 1c).
Octenidine release from laurate and palmitate coatings
The release of octenidine from fatty acid coatings was
measured over a period of 168 h via elution in PBS. As
demonstrated, octenidine release (Fig. 2) depends on the
used fatty acid as a coating component. Octenidine values
cumulated over 168 h for octenidine-laurate coated su-
tures showed released concentrations of 9.0 μg/ml/cm
(OL11), 19.4 μg/ml/cm (OL22), and 28.6 μg/ml/cm
(OL33). Elution data with palmitate as retarding agent
showed excellent delayed action. After 168 h, palmitate
coated sutures reached 0.8 μg/ml/cm (OP11), 1.0 μg/ml/
cm (OP22) and 10.8 μg/ml (OP33). The released amounts
at 168 h were referred to the absolute amount of octeni-
dine on coated sutures in percent (Fig. 3). The degree of
octenidine release calculated for octenidine-laurate coat-
ings results in 82 ± 10 % (OL11), 88 ± 17 % (OL22), and
87 ± 11 % (OL33). In comparison, octenidine-palmitate
coatings released only 7 ± 1 % (OP11), 5 ± 1 % (OP22),
and 33 ± 3 % (OP33) of the coated octenidine.
Biocompatibility study
L-929 cells exposed to eluates from octenidine-laurate coat-
ings showed metabolic activities of 77 ± 8 % (OL11), 48 ±
34 % (OL22), and 3 ± 1 % (OL33). Whereas, eluates from
octenidine-palmitate resulted in metabolic activities of 85 ±
27 % (OP11), 23 ± 22 % (OP22), and 1 ± 0.3 % (OP33). The
fatty acid coated references identified metabolic activities at
88 ± 13 % and 80 ± 13 % (lauric acid, palmitic acid). The
control group with uncoated sutures reach a metabolic ac-
tivity at 101 ± 10 % (Gunze) and Vicryl® Plus eluates dem-
onstrated activities at 99 ± 7 % (Fig. 4).
Discussion
Surgical site infections caused by sutures represent a ser-
ious problem in clinics. Antimicrobially coated sutures
may reduce suture-associated surgical site infections.
Bacterial contamination of the wound associated with
sutures occurs through the exogenous pathway. Patho-
gens are introduced either during surgery or from nat-
ural skin flora via wicking effect. In the presence of
suture materials a smaller amount of pathogens is often
sufficient to cause an infection compared to wounds
without foreign material [30]. In this study, we coated
Fig. 1 Antimicrobial long-term efficacies via agar diffusion tests using S. aureus lawns (2 × 108 cfu/ml) showed inhibition zones over time for
a octenidine-laurate coated sutures, b octenidine-palmitate coated sutures. Each coating type with three different octenidine concentrations 11,
22, and 33 μg/cm. c Vicryl® Plus as reference for commercial antimicrobial sutures
Fig. 2 Elution profiles in PBS buffer at 37 °C from a octenidine-laurate coatings and b octenidine-palmitate coated PGA sutures. Elution profiles
were determined for each coating type at 11, 22, and 33 μg/cm containing sutures. Horizontal lines depict the normalized drug contents per cm
coated suture, representing the limit of drug release for each drug concentration
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surgical sutures with 11, 22, or 33 μg octenidine per cm
length either in a palmitate or laurate fatty acid as retard-
ing carrier. The coated sutures were tested regarding their
antimicrobial efficacy, octenidine release and biocom-
patibility. We found that the antimicrobial activity of
octenidine coated sutures was as long as for triclosan
coated sutures, like Vicryl® Plus. The favorable anti-
microbial suture coating at 11 μg/cm was associated
with high biocompatibility.
According to antimicrobial efficacy, inhibition zones of
octenidine coated sutures on bacterial lawns were de-
tected for up to 9 days. In comparison to the triclosan
control group (Vicryl® Plus), the zones of inhibitions of
octenidine were smaller, although the amount of octeni-
dine on the sutures was significantly more than used
with triclosan. This discrepancy in inhibition zones can
be related to the presumably slower drug release by dif-
fusion of octenidine over time compared to triclosan.
This study was aimed to evaluate concentrations of
octenidine on sutures in the balance of antimicrobial ef-
ficacy and biocompatibility. Released octenidine concen-
trations are thus low, but that may be desirable to
protect the suture material, ensuring drug release for the
first critical week of wound healing. Both octenidine-
and triclosan coated sutures revealed a long lasting anti-
microbial effect, but degradation of absorbable suture
samples by hydrolysis caused termination of experiments
after the ninth day. Despite this degradation process, no
increase of inhibition zone could be detected as a pos-
sible indication of a sudden burst of octenidine release.
Nevertheless, the results of this in-vitro model must be
validated in-vivo prior to the application in humans, in
order to dismiss concerns for acute toxicity as a conse-
quence of the suture degradation process of octenidine
coated sutures. The time dependency of inhibition zones
did not differ greatly regarding the loaded drug concen-
trations of octenidine, so the three drug concentrations
are equally effective absorbable sutures, as the essential
protection is at least ensured for 9 days. Since the mech-
anism of wound healing provide an unaltered germ free
de novo synthesis of tissue, this time period of anti-
microbial protection should be sufficient to prevent in-
fection during the first essential phase of wound healing.
The assessment of octenidine kinetics showed a slow
continuous release over the first days of the experiment
for each coated suture. The release of octenidine was de-
layed by the used fatty acid carriers and the drug’s low
solubility in aqueous media. Triclosan coated sutures in
such media, like Vicryl® Plus assessed similar durations
of drug release [31]. Additionally, these data confirm our
measured efficacy over at least 9 days for Vicryl® Plus su-
tures, considering the fact that our tested sutures from
the EU containing less triclosan (max. 2.7 μg/cm), than
Fig. 3 The percentage of drug release related to the drug content
on coated sutures per cm length for each coating after 168 h of
elution in PBS buffer
Fig. 4 Metabolic cell activity of fibroblasts in the presence of eluates from octenidine coated sutures via WST-1 proliferation assay. L-929 mouse
fibroblasts were incubated with suture eluates and used references: lauric acid (LA), palmitic acid (PA), uncoated sutures (Gunze), and Vicryl® Plus.
All values were referred to cellular growth control, pure L-929 cells with culture media. Dashed line at 70 % pictures the level for acceptable lowering
of metabolic activity according to ISO 10993–5:2009 in order to declare biocompatibility of medical devices
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Vicryl® Plus sutures available in the US (max. 4.7 μg/cm)
[29]. Drug release kinetics over 7 days for octenidine
coatings showed, that all type of coatings retarded the
attached octenidine without full depletion. It is accepted
that the antimicrobial coating remains between the su-
ture filaments. Thus, the so-called wick effect of multi-
filament thread can be interrupted.
Referring to the drug carriers, palmitic acid in coatings
showed a much slower drug release characteristic in
comparison to lauric acid coatings demonstrating com-
parable antimicrobial efficacies. The ratio between re-
leased drug and loaded drug amounts on sutures after 7
days indicates that no coating type had fully washed-out
the antimicrobial agent octenidine. Similar to our previ-
ous findings [25], we found that palmitic acid carriers
delay the drug release more effectively than lauric acid
carriers do. As anticipated, the octenidine release was
dependent on the initial drug concentration in the su-
ture coatings. Antimicrobial action could be demonstrated
even for the lowest octenidine concentration (11 μg/cm)
over 9 days. Especially, the palmitic acid coatings may
guarantee a longer antimicrobial effect than lauric acid
carriers may. Therefore, we recommend a combination of
the drug octenidine with palmitic acid as carrier for long-
term antiinfective protection of surgical sutures to avoid
surgical site infections.
Biocompatibility, as defined by the ISO 10993–5:2009
guideline was reached for octenidine at the lowest concen-
tration (11 μg/cm) with both coatings consisting of pal-
mitic acid and lauric acid. Cytotoxicity tests of coated
octenidine sutures showed a strong dose dependency. An
increased drug concentration on loaded sutures, revealed
an increased cytotoxic reaction. Octenidine-palmitate and
-laurate sutures at 11 μg/cm showed similar metabolic ac-
tivities in comparison to pure lauric and palmitic acid
coated sutures. Compared to commercially available tri-
closan sutures (Vicryl® Plus), octenidine-palmitate coated
sutures also met the ISO standard for biocompatibility.
The comparison of octenidine coated sutures to chlor-
hexidine coatings, tested in a previous study [25], showed
different results in antimicrobial efficacy, drug release and
biocompatibility by using the same antiseptic drug
quantities. Octenidine sutures in lauric or palmitic acid
showed initial slightly smaller inhibition zones than of
chlorhexidine coatings during the first days of experi-
ment. However, the duration of the inhibition zones
lasted substantially longer for octenidine coatings, at
least up to 9 days. Octenidine-laurate coated sutures
compared to chlorhexidine-laurate coatings showed
similar released drug amounts at 96 h, but the time
span until flat drug kinetics were reached were much
longer. In addition, the drug release of octenidine-
palmitate sutures lasted longer and showed smaller re-
leased amounts at 96 h, referring to slower release
compared to chlorhexidine-palmitate coatings. The rea-
son for the longer drug release of octenidine can be re-
lated to the lower solubility of palmitic acid carrier and
octenidine itself in aqueous media, such as PBS. Add-
itionally, we observed that octenidine coatings were less
cytotoxic by using the same drug doses compared to
chlorhexidine coatings. Therefore, the drug release kin-
etics, antimicrobial activities and biocompatibility of
octenidine coated sutures are superior compared to
chlorhexidine coatings.
Our study has two main limitations: First, anti-
microbial coated sutures were exposed to only one
pathogenic strain, S. aureus. Herewith we wanted to
primarily demonstrate the feasibility of effective triclo-
san alternatives. The activity of octenidine against
other relevant bacteria as well as biofilm inactivation
against S. aureus has been published [32]. Therefore,
antimicrobial efficacy of coated sutures against other
common pathogens of wound infections should be
tested in the future. Second, the influence of the bio-
film formation on the antimicrobial efficacy of the
coated sutures was not simulated in our experiments.
Regardless, the use of octenidine is likely to circum-
vent any of the acquired resistances which are limit-
ing the extended use of triclosan.
Conclusions
In the current study, novel octenidine coatings to render
surgical sutures antimicrobial with three different con-
centrations based on palmitic/lauric acid were developed
and analyzed. All novel coatings proved high long-term
antimicrobial efficacy against S. aureus. Octenidine coat-
ings with drug concentration of 11 μg/cm on sutures
combine long-term antimicrobial efficacy up to 9 days
and slow drug release with demonstrated high biocom-
patibility. The drug release was dependent on the fatty
acid carrier and optimized delay was represented for
palmitate. Compared to the commercially available Vicryl®
Plus the antimicrobial efficacy of octenidine coated su-
tures was only slightly reduced. The potential disadvan-
tages of triclosan are severe toxic side products such as
dioxide and the promotion of multi drug resistance, which
justifies the search for alternative substances for future
use. However, despite these promising results, it needs to
be clearly pointed out that it cannot be concluded from
our findings that octenidine coated sutures are superior to
the triclosan coated sutures. Therefore, further studies are
necessary to prove that octenidine coated sutures repre-
sent a serious alternative to the currently commercially
available triclosan coated sutures.
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